Product image of Nexviazyme (avalglucosidase alfa-ngpt) (Avalglucosidase Alfa) 100 mg/10mL INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION supplied by GNH India

Nexviazyme (avalglucosidase alfa-ngpt)

Active Ingredient:
Avalglucosidase Alfa
Form:
INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
Brand:
Nexviazyme
Origin:
USA

Nexviazyme (avalglucosidase alfa-ngpt) (Avalglucosidase Alfa INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION) 100 mg/10mL

Nexviazyme (avalglucosidase alfa) is an FDA-approved orphan drug developed by Sanofi Genzyme for the treatment of late-onset Pompe disease, a rare genetic neuromuscular disorder. It is administered intravenously and represents an advance in enzyme replacement therapy for this debilitating condition. The drug falls within the neurology and genetic medicine therapeutic categories.

Strength

100 mg/10mL

Pack Size

1 VIAL, SINGLE-DOSE in 1 CARTON (58468-0426-1) / 10 mL in 1 VIAL, SINGLE-DOSE

Manufacturer / TM Owner

Sanofi Genzyme

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

Indications & Clinical Uses

  • Nexviazyme is indicated for the treatment of late-onset Pompe disease (LOPD), a rare autosomal recessive lysosomal storage disorder caused by deficiency of the acid alpha-glucosidase (GAA) enzyme. This enzyme deficiency leads to accumulation of glycogen in skeletal muscles, cardiac muscle, and the nervous system, resulting in progressive muscle weakness, respiratory compromise, and functional decline. Nexviazyme is designed for patients with confirmed GAA deficiency who present with muscle weakness and other clinical manifestations of LOPD. The drug works by providing exogenous acid alpha-glucosidase enzyme through intravenous infusion, enabling cells to break down accumulated glycogen and reduce pathological storage. This mechanism helps stabilize or improve muscle function and respiratory capacity in affected patients. Nexviazyme is particularly beneficial for patients who may have had inadequate response to or intolerance of previous enzyme replacement therapies.

Side Effects

  • Common adverse events associated with Nexviazyme include infusion-related reactions such as fever, chills, flushing, headache, and myalgia. Serious adverse events may include anaphylaxis, severe hypersensitivity reactions, and immune-mediated responses. Patients may develop anti-drug antibodies that could affect therapeutic efficacy. Monitoring requirements include regular assessment of muscle strength, respiratory function, and cardiac status. Infusion reactions should be managed with appropriate premedication and slow infusion rate titration. Laboratory monitoring for antibody formation and enzyme activity levels is recommended during treatment.

Precautions & Warnings

  • Nexviazyme is contraindicated in patients with severe hypersensitivity to avalglucosidase alfa or any excipients. Caution is warranted in patients with history of anaphylaxis or severe infusion reactions. Pregnancy category data should be reviewed; use only if benefits outweigh risks. Pediatric use requires careful consideration as safety and efficacy in children differ from adults. Patients with compromised renal or hepatic function should be monitored closely, though dose adjustment protocols are not well-established. Immunocompromised patients may require special monitoring. Concurrent use of immunosuppressive agents should be evaluated on a case-by-case basis.

Avoid Interactions

  • Limited specific drug-drug interactions have been formally documented for Nexviazyme. However, concurrent use of immunosuppressive medications may alter immune responses and antibody formation. Patients receiving anticoagulants should be monitored due to potential bleeding risk during infusions. No significant food interactions are known. Caution is advised when combining with other intravenous therapies that may increase infusion reaction risk. Healthcare providers should review all concurrent medications and supplements with patients before initiating therapy.

Frequently Asked Questions

Nexviazyme is used to treat late-onset Pompe disease (LOPD), a rare genetic disorder characterized by acid alpha-glucosidase enzyme deficiency. It helps reduce the accumulation of glycogen in muscles and improves muscle strength and respiratory function in affected patients.

Nexviazyme is administered as an intravenous infusion. The infusion is typically given at a controlled rate to minimize infusion-related reactions. Treatment frequency and dosing are individualized based on patient response and tolerance.

Common side effects include infusion-related reactions such as fever, chills, headache, and muscle pain. Most reactions are mild to moderate and manageable with premedication and slower infusion rates. Serious hypersensitivity reactions are rare but require immediate medical attention.

Nexviazyme is manufactured by Sanofi Genzyme, a subsidiary of Sanofi specializing in rare genetic and specialty diseases.

Yes, Nexviazyme received FDA orphan drug designation for the treatment of Pompe disease. This status recognizes its development for a rare disease affecting a small patient population and provides regulatory incentives including extended market exclusivity.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Avalglucosidase Alfa

Nexviazyme 100 mg

Nexviazyme 100 mg

100 MG POWDER FOR SOLUTION

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT